Skip to Main Content

Advertisement

Skip Nav Destination

Issues

Cancer Immunology Research

Cancer Immunology Research, launched in 2013 with Glenn Dranoff as founding Editor-in-Chief, is published by the AACR. The Journal illuminates the interplay between tumors and the immune system, with Robert D. Schreiber and Philip D. Greenberg serving as the Editors-in-Chief.

Table of Contents

What We're Reading

In the Spotlight

Cancer Immunology at the Crossroads

Review

Priority Briefs

EA is demonstrated to inhibit MSS colorectal cancer progression and enhance efficacy of anti–PD-1 by boosting antitumor responses. Combination EA and anti–PD-1 is highlighted as a feasible and safe treatment option for MSS colorectal cancer.

Deletion of an ATPase in T cells promotes ROS accumulation, tonic signal transduction, and T-cell exhaustion due to decreased intracellular K+. Data provide a deeper understanding of T-cell ion transport and highlight how it can impact antitumor responses.

Interferons are essential components of the immune response against tumors. The authors identify a possible approach to induce interferons in the tumor microenvironment and promote the effectiveness of other immune therapies relying on preexisting interferon signaling.

Research Articles

This work provides evidence for combining antibody therapies that involve cell types from both the adaptive and innate arms of the immune system. The data could inform future treatment practices and expand regimens of antibody-based immunotherapies for cancer.

The authors show that inhibition of MIF tautomerase activity blocks exosomal MIF–induced MDSC differentiation and suppresses pancreatic cancer growth in mice, suggesting translational potential for this approach.

Active Notch signaling in pancreatic TAMs is demonstrated to regulate their immunosuppressive phenotype. Notch signaling inhibition sensitizes pancreatic tumors to immune checkpoint blockade by reshaping the tumor microenvironment, highlighting targeting Notch signaling as a potential pancreatic cancer immunotherapy.

Infiltrating IL17A+ γδ T cells are demonstrated to have antitumoral activity in GIST and can be further activated by tumor oncogene inhibition. The data highlight the potential of this rare, but potent, cell type as an immunotherapeutic target.

The authors use a morphology-guided transcriptomic approach to resolve the spatial complexity of TNBC samples to analyze response to NAC, finding information on the multidimensionality of TNBC that may allow prediction of tumor behavior and NAC response.

Acknowledgment to Reviewers

Close Modal

or Create an Account

Close Modal
Close Modal